Mazo, G. and Kibitov, A. (2017) “Genetic Markers of Metabolic Side-Effects Risks in Second-Generation Antipsychotic Therapy”, Current Therapy of Mental Disorders, (4), pp. 2–10. doi: 10.21265/PSYPH.2017.43.8415.